Holen Sie sich die Stockscreener-App
31.40
1.04%
-0.33
Vorhandelsmarkt:
31.50
0.10
+0.32%
Schlusskurs vom Vortag:
$31.73
Offen:
$31.75
24-Stunden-Volumen:
1.58M
Relative Volume:
0.46
Marktkapitalisierung:
$3.55B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-99.15M
KGV:
-33.76
EPS:
-0.93
Netto-Cashflow:
$-74.25M
1W Leistung:
-6.32%
1M Leistung:
-15.55%
6M Leistung:
-8.77%
1J Leistung:
-6.16%
1-Tages-Spanne:
$31.20
$32.14
1-Wochen-Bereich:
$31.20
$34.98
52-Wochen-Spanne:
$18.92
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Vergleichen Sie VKTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
31.40 | 3.59B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Goldman | Neutral |
| 2025-02-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-07 | Eingeleitet | Citigroup | Neutral |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-11 | Eingeleitet | JP Morgan | Overweight |
| 2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-07 | Eingeleitet | Jefferies | Buy |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
2 Biotech Stocks Set to Rebound in 2026 - The Globe and Mail
Viking Therapeutics’ Obesity Drug Candidate Gains Momentum with Phase 2 Publication - AD HOC NEWS
Assessing Viking Therapeutics (VKTX) After Recent Pullback And Ongoing Pipeline Headlines - simplywall.st
Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? - Yahoo Finance
Viking Therapeutics Stock Analysis: Growth Narrative Remains Compelling - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Advances Obesity Drug Development and Expands Metabolic Disease Pipeline - Insider Monkey
The Technical Signals Behind (VKTX) That Institutions Follow - Stock Traders Daily
3 Growth Stocks to Invest $1,000 in Right Now - The Motley Fool
The Best Stocks to Invest $40 in to Start the New Year Off Right - Finviz
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts - sharewise.com
Viking Therapeutics Shares Slide Amid Analyst Downgrade and Earnings Concerns - AD HOC NEWS
Viking Therapeutics (VKTX) Is Down 5.0% After Phase 2 VK2735 Data And Phase 3 Updates – Has The Bull Case Changed? - simplywall.st
Viking Therapeutics, Inc. (VKTX) stock dips while market gains: Key facts - MSN
Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly - FinancialContent
Assessing Viking Therapeutics (VKTX) Valuation As Shares Rebound Over The Past Week - Yahoo Finance
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 - Finviz
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts - Yahoo Finance
Viking Therapeutics (NASDAQ:VKTX) Downgraded by Zacks Research to Strong Sell - MarketBeat
Assessing Viking Therapeutics (VKTX) Valuation After VK2735 Phase 2 Success And Phase 3 Trial Progress - simplywall.st
Can Viking Therapeutics Make a Turnaround This Year? - NAI500
2 Bargain Stocks You Can Buy for Less Than $100 Right Now - The Globe and Mail
Viking Therapeutics' Price Target of $93.39 Implies 175% Upside Potential - Intellectia AI
Viking Therapeutics (VKTX) Faces Challenges, Analysts Set Price Target of $93.39, Potential Upside of 175% - Intellectia AI
1 Stock That Could Soar by 175%, According to Wall Street - Finviz
Upcoming Oppenheimer Virtual Meeting Featuring VKTX - GuruFocus
What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026? - AOL.com
3 Biotech Stocks That Look Like "Sure-Fire" Winners in 2026 - Finviz
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 - MarketBeat
Viking Therapeutics, Inc. (VKTX) Investor Outlook: A Biotech Stock with 175% Potential Upside - DirectorsTalk Interviews
Published on: 2026-01-18 12:53:17 - baoquankhu1.vn
Viking Therapeutics Stock (VKTX) Opinions on VK2735 Obesity Drug Results - Quiver Quantitative
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Volume Summary: What is AEISs valuation compared to sector2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Viking Therapeutics: A Stock at a Crossroads Amid Obesity Drug Ambitions - AD HOC NEWS
Is Viking Therapeutics (VKTX) Now Attractive After A Strong DCF Upside Signal - Yahoo Finance
Viking Therapeutics Stock Navigates a Week of High Volatility - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
The Escalator: AstraZeneca, Viking Therapeutics, VML Health and more - Medical Marketing and Media
M&A Speculation Fuels Rally in Viking Therapeutics Shares - AD HOC NEWS
Why Viking Therapeutics (VKTX) Is Up 6.1% After VK2735 Phase 2 Obesity Data And Phase 3 Progress - simplywall.st
Viking Therapeutics (VKTX) Soars 11.9% on Strong Weight Loss Market Outlook - Finviz
VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals - Stocktwits
Viking Therapeutics Unveils Promising Phase 2 Clinical Success, Fuels Stock Surge - timothysykes.com
Precision Trading with Viking Therapeutics Inc. (VKTX) Risk Zones - Stock Traders Daily
Viking Therapeutics (NASDAQ:VKTX) Trading 8.3% HigherShould You Buy? - MarketBeat
$VKTX stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals - TechStock²
SG Americas Securities LLC Acquires 81,519 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics: Positioning in the Competitive Obesity Drug Arena - AD HOC NEWS
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):